Ascendis Pharma Investigational Site

Canton, Ohio 44718

0 studies enrolling now · 3 studies all time

What they study most

2L+ Cervical Cancer, Advanced Solid Tumor, HPV-associated Cancers, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma HNSCC, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC), Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Platinum-resistant Ovarian Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer

Studies at this site

• A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors — Stopped early
• A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies — Running, not enrolling
• TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma — Stopped early